Sandeep Sahay, MD, FCCP, director of the Pulmonary Hypertension Program, Houston Methodist Hospital, previews key topics of this year's American Thoracic Society (ATS) conference.
The American Thoracic Society (ATS) 2025 International Conference is highly anticipated for its comprehensive coverage of pulmonary research, from basic science to clinical trials, says Sandeep Sahay, MD, FCCP, director of the Pulmonary Hypertension Program, Houston Methodist Hospital.
This transcript was lightly edited; captions were auto-generated.
Transcript
What do you anticipate will be key themes at ATS 2025?
The American Thoracic Society meeting is always an exciting conference for which we always look forward to. What I really like about ATS is that it provides a whole spectrum of insight, knowledge, from basic science to the clinical and the clinical trials. I'm looking forward to some interstitial lung disease clinical trial results, which probably will be presented soon at the ATS meeting and will publish simultaneously. I'm also looking forward to exciting stuff from the basic science in the pulmonary hypertension area. Apart from that, for the general pulmonology diseases like COPD [chronic obstructive pulmonary disease] and asthma, there is so much of groundbreaking research which gets presented at ATS. I'm always looking forward to this.
This year, the American Thoracic Society has started a Respiratory innovation Summit, which is really exciting, where they are collaborating with the industry partners [on] how medicine can be advanced to bring new therapeutics in different diseases. Additionally, I'm also looking forward to a patient advocacy panel on which I am also participating, along with the thought leaders from the American Thoracic Society. I think these will be perfect and excellent opportunities for patients to express their viewpoints and the scientific leaders to learn from that, so that we can advance our patient management, patient care, and science in a more meaningful way, which is more relevant to our patients.
What do you enjoy most about attending ATS?
I always enjoy the ATS meeting. First, I love San Francisco. Second, it's always fun to meet all your national, international colleagues who travel to attend the meeting, and it's nice to hear their viewpoints on different topics, and when they're presenting their research and advances in the science in the last year. It's also a very good opportunity to meet the new talent, the younger talent, the fellows and the residents who are interested in the disease space, and to encourage them and provide mentoring opportunities. ATS has a very strong mentoring program, which really helps to support early career physicians or specialists or fellows and residents in training for their career development.
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More